Insights 
VT 
Alnylam Pharmaceuticals (ALNY) focuses on therapeutics using ribonucleic acid interference and trades on Nasdaq under the “ALNY” ticker. It recently ended a pullback at $442.51 and predicts a rally towards $494.95 to $511.13. The firm warns that pursuing the rally is risky, suggesting buying at the next correction point.
The Elliott Wave analysis shows ALNY ended earlier phases with a pullback at $31.38 in 2016, followed by a high of $140 in 2025. Since then, it continued rising, marking key stages along with corrections, notably after reaching $242.97. It anticipates more growth before the next, expected correction.
Since April 2024, ALNY has marked successive highs, reaching $304.39 in mid-2025, and suggests further movements in its current phase. The wave analysis places a projected high of around $511.13, potentially extending to $570.76 before a correction. Despite continuing growth, it remains cautious about immediate further investments, focusing on upcoming corrections.
Legal and market disclaimers emphasise that information involves potential risks and uncertainties. It’s intended for informational purposes, without endorsing specific buy or sell actions. As investment entails significant risk, decisions should be based on independent research.
Alnylam Pharmaceuticals has extended its rally from the lows we saw in April and July of 2025. The stock has now reached the minimum target area between $494 and $511, making new long positions risky at these levels. We see this as the final stage of the current upward move.
This powerful surge through September and early October was largely driven by positive late-stage trial results for Zilebesiran, the company’s hypertension drug. However, the broader Nasdaq Biotechnology Index (NBI) has shown signs of weakness in the past month, falling 4% since late September 2025. This cooling of the sector suggests a headwind for even the strongest performers like Alnylam.
For derivative traders, this indicates it may be time to reduce exposure to long call positions and take profits. With the stock near its price targets, the risk of a sharp pullback outweighs the potential for further immediate gains. Cautious traders could consider buying protective puts to guard existing stock holdings against the expected downturn.
The primary strategy in the coming weeks is to remain patient and wait for the next corrective pullback. We will be watching for a dip to unfold, which would offer a much better entry point for establishing new bullish positions. This correction is the next major buying opportunity we are anticipating.
We saw a similar pattern when the stock pulled back sharply in the first half of 2024, which set up the powerful rally we are seeing now. As long as any coming correction stays above the July 2025 low of around $206, the larger uptrend remains valid. That level is the critical support we will be monitoring.
